Hi [[ session.user.profile.firstName ]]

Pharma data as an asset: how to become information centric

Life Sciences and pharma are moving to a more data driven approach. Data is seen as an asset, yet not treated as such, with levels of investment not matching the value that reusable data will bring across the R&D value chain. Effective AI, ML and predictive outcomes are dependent on access to clean, reusable data and getting that clean data is often hard, time consuming and challenging.

FAIR Data principles provide you with the perfect blueprint to overhaul your data processes.

In this webinar, Dr Martin Romacker – Principal Scientist, Data and Information Architecture, Roche will walk us through how to access clean reusable data that will drive value across the R&D value chain and will outline areas where Roche is taking action to enable better and more effective data reuse.
Recorded Jul 8 2020 59 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Dr Martin Romacker
Presentation preview: Pharma data as an asset: how to become information centric

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • 「R&Dにおけるデジタルトランスフォーメーション~Scientific dataの活用~」 Aug 24 2021 4:15 am UTC 45 mins
    ライフサイエンス データ&アナリティクス ソリューションマネージャー 齋藤 美里
    - データ活用によるR&Dの加速
    - 現状と課題
    -フルテキストから得られる情報
    - グローバルにおける事例

    ※所属機関のメールアドレスよりお申込みください。
  • Reaxys基礎編「なぜあなたの反応・化合物検索ではノイズが多いのか?~ノイズを減らす構造描画とフィルター機能のノウハウ~」 Jul 15 2021 4:15 am UTC 45 mins
    カスタマーコンサルタント:今田 泰史
    Reaxysの初心者から中級者まで使えるMarvin JSでの構造描画テクニックについてご紹介。ノイズが出てしまう原因を解説し、いかにノイズを解消するかをデモンストレーション致します。また、検索結果を得た後に絞り込むためのフィルター機能の活用の仕方も併せて解説します。

    ※所属機関のメールアドレスよりお申込みください。
  • Next generation synthesis planning using AI for chemists Jul 13 2021 4:00 pm UTC 60 mins
    Mandar Bodas, Abhinav Kumar, Jurgen Swienty-Busch
    Rapid navigation of increasingly complex druggable chemical space is critical for innovative drug design. However, chemical synthesis and route design is still a significant challenge. In this session, we will discuss recent development in predictive retrosynthesis. Also, we explore how Reaxys collaborated with Pending.AI, a startup led by Prof. Mark Waller, to develop a ‘deep learning’ solution that predicts new synthesis routes with high accuracy for creating small organic compounds. The presentation will focus on:

    1. Science behind AI powered predictive retrosynthesis
    2. Reaxys predictive retrosynthesis overview and demo
    3. Discussion on benefits, limitation of technology and future roadmap

    Speaker bios:
    Mandar Bodas, Solution Sales Manager - Life Sciences, Elsevier (https://www.linkedin.com/in/mandar-bodas-b360314/)
    Abhinav Kumar, Head of Strategy and Business Development - Chemistry Solutions, Elsevier (https://www.linkedin.com/in/abhinavkumar8/)
    Jurgen Swienty-Busch, Director of Product Management - Chemistry Solutions, Elsevier (https://www.linkedin.com/in/jsb2018/)
  • How AI disease modeling can support precision medicine for glioma/other cancers Recorded: Jun 10 2021 60 mins
    Dr Anton Yuryev, Biology Director, Elsevier
    Join biological modeling expert Dr. Anton Yuryev for an exclusive look at disease modeling that informed precision medicine decisions.

    In this project, OMICs data for patients with the brain cancer diffuse intrinsic pontine glioma (DIPG) was analyzed using an Elsevier biology knowledge graph and complementary software to develop a molecular disease model. This model was then leveraged to find FDA-approved drugs inhibiting the disease mechanism.

    In this webinar, you’ll see:
    - The workflow for importing patient OMICs data, projecting onto an Elsevier biology knowledge graph, and building a unified consensus disease model
    - The workflow for finding and ranking drugs that could inhibit the disease mechanism, and how this drug selection was refined
    - The mutations found in all DIPG patients and how common these are in other cancer types

    The webinar includes a Q&A session with Dr. Yuryev.
  • Reaxys Patent Expansion 2021: An improved Competitive Intelligence Recorded: May 25 2021 48 mins
    Jen Teske, Solution Sales Manager and Robert Niebergall, Customer Consultant
    Reaxys is growing. The leading knowledge solution for small molecule design and synthesis has exponentially augmented its patent content to bring you competitive intelligence for biological target validation.

    With AI-powered extraction, primary target indexing, and quality control through domain experts and data scientists, the rapidly growing content of Reaxys grants insights into risks in a rapidly evolving patent landscape.

    Keep your finger on the pulse of the market:
    • Access newly published patents, covering 105 offices and 170 IPC classes
    • Use the only solution that translates non-English language abstracts and claims
    • Capture comprehensive results with indexed primary targets and synonyms
    • Do competitive deep-dives with advanced searches for patent assignee
    • Get alerts on the latest patents, available just 5 days after publication
  • COVID-19 Vaccines: An Update on Research & Global Availability Recorded: May 12 2021 62 mins
    John McConnell | Editor-in-Chief, The Lancet Infectious Diseases (London, United Kingdom)
    Join John McConnell, Editor-in-Chief of The Lancet Infectious Diseases to update yourself on the latest scientific viewpoints regarding the workings of the COVID-19 vaccines. In this professional webinar, John will cover areas such as:
    • Effectiveness of vaccines in preventing disease, including variant viruses
    • Vaccine safety – reactogenicity, anaphylaxis, clotting disorders, Bell’s palsy
    • What vaccines are available and their mechanisms of action
    • The path to making vaccines available worldwide
    • How has the pandemic affected the research landscape
    Moreover, you will get the opportunity to secure answers to your own pressing questions. You won’t want to miss this valuable webinar.

    About the presenter:
    John McConnell studied clinical microbiology and parasitology at the University of East London, before spending 6 years researching septic-shock-related topics at the Royal Postgraduate Medical School, Hammersmith Hospital, London (now part of Imperial College London). He joined The Lancet in 1990 as a peer-review editor before becoming the first Web Editor in 1996. In 2001, John was the founding editor of The Lancet Infectious Diseases. He has appeared as an expert commentator on BBC, ITV, Channel 4, Sky News, Al Jazeera, CNBC, CNN, and CCTV America. In the past year, The Lancet Infectious Diseases has published some of the most impactful research on COVID-19.
  • Creating Knowledge Graphs from Literature, 29 April 2020 Recorded: Apr 30 2021 34 mins
    Joe Mullen, Lead Technical Consultant at SciBite
    Organizations produce data and ingest externally generated data at a rapid pace. Holistic views of multiple data sources allow for inferences to be made that would otherwise remain unseen. In order to take holistic views of this data, it is critical that they are aligned to standards and that intuitive data structures are utilized to enable complex querying of the integrated dataset.

    In this short webinar our Lead Technical Consultant Joe Mullen will explain how SciBite’s semantic enrichment technology is being used to facilitate the production of Knowledge Graphs.

    We will explain how the SciBite stack can be used for the extraction of semantic triples from literature as well as the harmonization and integration of these with data from both external and internal structured data sources.

    For more upcoming SciBite webinars visit our website: https://www.scibite.com/events/
  • Reaxys Patent Expansion 2021: An improved Competitive Intelligence Recorded: Apr 23 2021 44 mins
    Sejin Kim, Customer Consultant
    • Information that can be retrieved through patent information provided by Reaxys
    • Patent update process
    • Use case: How to search patents using Biological Targets
  • Reaxys Patent Expansion 2021: An improved Competitive Intelligence Recorded: Apr 16 2021 48 mins
    Dr Nilesh Rane, Solution Consultant
    • Information that can be retrieved through patent information provided by Reaxys
    • Patent update process
    • Use case: How to search patents using Biological Targets
  • Managing scientific literature for drug/device development and medical affairs Recorded: Mar 18 2021 36 mins
    Heather Desmarais, MLS (President, HJD Consulting LLC)
    Scientific literature is a critical component to virtually all aspects of a life science enterprise, including Medical Affairs, Pharmacovigilance, and R&D. However, the process of curating and sharing literature can lead to significant challenges in organizing content, facilitating collaboration, and copyright compliance.

    In many cases, reference management tools are used to manage the large amounts of literature that accumulate over time. While these tools are helpful for developing bibliographies, a more robust approach to managing literature should be considered in order to effectively collaborate and centralize information.

    Especially in the remote-working era, a proper method of literature management can benefit your entire organization. Learn how best practices in literature management can keep you and your colleagues up to date on new developments, support collaboration, enable workflows and more.

    Heather Desmarais is a knowledge and information management consultant, as well as the founder and principal of HJDesmarais Consulting LLC. Heather worked in academic and corporate information centers before launching her consulting business in 2015. She received her MLS from the State University of New York at Albany and is based in the Boston area.
  • Use Reaxys® Reaction Data to Create Chemistry Models Recorded: Feb 16 2021 50 mins
    Dr Michael Collingsworth and Dr Eric Gilbert
    It’s an exciting time for those working in predictive reaction chemistry – the different algorithms and approaches available, and the outcomes these are helping to generate. Having a scalable environment that enables model deployment back out to bench chemists is key.

    In this webinar Dr Michael Collingsworth (Elsevier, Reaction Workbench Product Owner) and Dr Eric Gilbert (Elsevier, Chemistry Consultant), will show the workbench environment, and demonstrate what it can enable, including efforts to create a model to predict reaction conditions.

    If you are interested in any of the following areas, the Entellect® Reaction Workbench can help you and your team.

    -Benchmark published models using Reaxys reaction data
    -Access harmonized Reaxys reaction data for predictive modeling
    -Creating your own predictive models
    -Having a scalable and simple way to deploy your work back to your bench chemists
  • Building smart and effective biomedical literature search strategies Recorded: Jan 26 2021 52 mins
    Jean Dominique Pierret and Caroline Muller
    Biomedical literature plays a key role in the development of effective and safe drugs. To avoid missing important insights it is critical your literature search is comprehensive. Additionally, to be efficient, you would like to avoid retrieving too many non-relevant articles.

    In this webinar, scientific information experts Dr. Jean Dominique Pierret (Elsevier) and Dr. Caroline Muller (Bioledge) will explain how to quickly and efficiently focus your search on what is essential to you. Wherever you work in drug development, this webinar is relevant for you.

    Using different databases and real-world examples, they will explain how to work with search operators to retrieve relevant literature.

    What will be discussed during this webinar will allow you to address topics such as:
    • Creating a selection of articles on bispecific antibodies for cancer treatment
    • Following trends in stents for heart infarction
    • Closely monitoring the safety concerns of a specific marketed drug
    • Review the latest literature about the specificity of a analytical test
    • And more
  • Property Searching in Reaxys and Related Chemistry Databases Recorded: Dec 10 2020 60 mins
    Prof. Damon. D. Ridley
    How do we find reliable spectroscopic, physico-chemical or biochemical properties of chemical substances quickly?
    Prof. Damon Ridley will walk us through the exciting world of chemical compound property searching. He is illustrating what databases are available, most reliable and comprehensive enough to serve your scientific needs.
  • The Role of Scientific Literature in Pharmacovigilance: Challenges, Solutions & Recorded: Dec 10 2020 138 mins
    Dr Avinash Kakade, Dr Manoj Swaminathan, Dr Jean-Dominique, Dr Dhanraj,Dr Kabil Kalathingal, Mr Prashant Joshi, Ms Michelle
    This 2-hour webinar brings together leading individuals and thought leaders from Pharmacovigilance sharing best practices and strategies on how drug safety professionals can overcome the research challenges in this Covid-19 environment.
  • Text Mining to Identify Emerging Trends in Pancreatic Cancer Literature Recorded: Nov 19 2020 33 mins
    Dr. Eric GIlbert, Professional Services
    Text mining is one way to analyze emerging trends in research literature. Here we show how Elsevier’s text mining tool can be used to identify emerging trends using pancreatic cancer as an example. Firstly, trending taxonomy terms are identified by fitting a regression line to the normalized quarterly counts of publications in which the term is found. Then regression parameters are used to filter for terms that have the greatest fold change in publication counts over the time period. The workflow describing the capturing of trending terms will be described in detail. Several captured terms will be highlighted to demonstrate the insights that can be gained in this type of analysis.

    About the speaker:

    Dr. Eric Gilbert is an accomplished medicinal chemistry research scientist with over 15 years of experience in drug discovery at Pfizer, Schering-Plough, and Merck. He is the author and coauthor of 16 publications and an inventor for 22 issued US patents. Eric possesses a unique combination of synthesis and drug discovery experience along with an extensive data science background.
  • How scholarly literature can support Medical Science Liaisons Recorded: Nov 10 2020 43 mins
    Dr. Nadège Krebs
    Medical Affairs specialists facilitate the flow of unbiased information from science to pharma as medical science liaisons. This efficient exchange between the medical community and the pharmaceutical industry is of paramount importance. It helps pharmaceutical companies reduce healthcare costs and better meet consumer expectations. Medical information specialists have become the ‘go-to partner’ within pharma organizations.

    Comprehensive biomedical literature plays a critical role in synthesizing important literature on on drug safety, pharmacoepidemiology, key opinion leaders (KOLs) and much more.In this webinar, you will learn how you can use Embase to extract and synthesize the most relevant information from a sea of data. Embase is the world’s most comprehensive biomedical research and literature database.

    Dr. Nadège Krebs will discuss how to:
    • Find the latest reports on the burden of a disease or its epidemiology
    • Identify the pharma KOLs to build partnerships
    • Gather literature on the latest clinical trials for colleagues and/or patients

    Discover why 8 international organizations and regulatory authorities recommend Embase.

    About the speaker: Nadège is an Embase expert and a solution consultant for corporate companies across Europe. She has helped different stakeholders to answer questions ranging from disease burden to medical devices comparisons to drug pharmacovigilance using Embase.
  • 特定ターゲットに対して活性を示す化合物の同定 ~Reaxys/Reaxys Medicinal Chemistryを用いたSAR解析~ Recorded: Nov 5 2020 39 mins
    鈴木 直子
    生物活性データを保持するReaxys Medicinal ChemistryをReaxys上で利用し、特定のターゲットへ高い親和性をもつコア骨格を保持した化合物を同定する方法を紹介する。
    また、それらが特許範囲に含まれるか、またどうやって合成するかについての検討方法についても紹介する。
  • Optimizing personalized drug dosing for patients with drug-specific PK models Recorded: Oct 29 2020 56 mins
    Olivier Barberan/Aurélie Lereclus
    Fully understanding the Pharmacokinetic properties of a drug is crucial for safe administration of drugs. Too high levels of exposure to a drug can cause severe adverse events whereas a too low exposure can result in the drug not being effective. Differences between patients such as age, gender, kidney status, genotype, smoker, organ impairment or other individual characteristics can significantly influence the pharmacokinetics of a drug.

    In clinical research, Pharmacokinetic properties are often determined on homogenous population of healthy volunteers. Based on these data, there is often only one recommended dose for all patients (for example 200mg, twice a day). This can result in unexpected dangerous underexposure or overexposure when administering drugs in a highly heterogenous real-world populations. Therefore, adjusting drug dosing to the characteristics of individual patients can significantly reduce adverse events and improve clinical outcomes.

    Join us for this partner webinar where Elsevier and ExactCure will discuss:

    *The importance of modelling PK behavior of drugs based on patient characteristics to adjust dosing at individual patient level
    *The progress in developing phenotype and genotypic high quality dynamic Pharmacokinetic models
    *The need for high quality data to build Pharmacokinetic data models
    *How Elsevier and ExactCure are working together to build personalized drug-specific exposure models that allow the prediction of pharmacokinetic properties
  • Model-Based Strategy to Guide the Choice of Clinical Doses for ADC Recorded: Oct 27 2020 55 mins
    Julie Desrivot Quénelle, PKPD Project Lead at Pierre Fabre
    Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving the therapeutic index, however the greatest challenge to date for developing ADCs is a narrow therapeutic window that often results in toxic effects occurring before an ADC reaches its maximally efficacious dose.

    The PK/PD scientists at Pierre Fabre have developed the novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate (ADC W0101).

    In this webinar, Dr Julie Desrivot Quénelle, the PKPD Project Lead at Pierre Fabre, will uncover the science behind the scenes and talk about model development characterizing:

    1) The relationship between PK and tumor growth in xenograft mouse allowing to calculate the tumor-static concentrations (TSC), i.e. drug concentration leading to tumor volume stabilization. The comparison versus ADC PK parameters help to anticipate potential efficacious dosing regimen in human.

    2) The ADC-induced toxicity in animal species and in patients. These models were further used to simulate potential patient outcomes, and to identify a safe dose range in clinical setting.

    Presenter: Julie Desrivot Quénelle, PKPD Project Lead, Pierre Fabre
    Host: Olivier Barberan, Director of Translational Medicine Solutions, Elsevier
  • DNA-encoded libraries in drug discovery Recorded: Oct 14 2020 78 mins
    Dr. Alex Satz; Dr. Andreas Brunschweiger
    DNA-Encoded library (DEL) screening is now commonly used in the pharmaceutical industry to find novel chemical matter that modulates protein targets of interest. A DEL is a mixture of millions of drug-like small-molecules, where each molecule is conjugated to a DNA-oligomer that encodes its chemical structure. The composition of a DEL mixture can be readily interrogated before and after interaction with a protein target by Next Generation Sequencing, and small-molecules that selectively bind the target identified.

    We’re excited to invite you to a webinar on this topic that Dr. Alex Satz, senior director of DEL strategy and operations at WuXi AppTec, will talk about the current learnings in DEL design, synthesis, and screening, followed by a presentation from Dr. Andreas Brunschweiger of TU Dortmund University on research demonstrating the role of cheminformatics and DNA-encoded chemistry in compound identification.

    About speakers:
    Alex Satz has 15+ years experience building DNA encoded library (DEL) platforms, and is currently the senior director of DEL strategy and operations at WuXi AppTec. Prior to WuXi AppTec, Alex led the Roche DEL platform in Basel Switzerland, and helped to develop the first industrial-scale DEL platform at Praecis Pharmaceuticals and GlaxoSmithKline.
    Andreas Brunschweiger is a group leader at the Departmend of Chemistry and Chemical Biology of TU Dortmund University. His current research interests include the development of computer-assisted tools for DNA-endoced library design, synthesis and encoding strategies that expand the chemical space of DNA-encoded libraries, and asssays for hit identification.
Webinars supporting your innovation, compliance needs, and safety
Realize the potential of data-driven drug discovery and development with solutions that help you increase research efficiency and ensure a thriving R&D pipeline.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Pharma data as an asset: how to become information centric
  • Live at: Jul 8 2020 2:00 pm
  • Presented by: Dr Martin Romacker
  • From:
Your email has been sent.
or close